Company Encyclopedia
View More
name
LIFERIVER
688317.SH
Shanghai ZJ Bio-Tech Co., Ltd. engages in the research and development, production, and sale of molecular genetic diagnostic reagents, instruments, and equipment in China. The company was founded in 2005 and is based in Shanghai, China.
349.86 B
688317.SHMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
D
Health Care SuppliesIndustry
Industry Ranking40/41
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-4.01%D
    • Profit Margin-109.37%E
    • Gross Margin29.61%C
  • Growth ScoreD
    • Revenue YoY-36.38%E
    • Net Profit YoY22.05%B
    • Total Assets YoY-5.47%D
    • Net Assets YoY-10.06%D
  • Cash ScoreE
    • Cash Flow Margin-91.43%D
    • OCF YoY-36.38%E
  • Operating ScoreE
    • Turnover0.03E
  • Debt ScoreA
    • Gearing Ratio8.79%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    LIFERIVER released its performance for the first three quarters, with a net loss attributable to the parent company of 29.38 million yuan

    According to the Zhitong Finance APP, LIFERIVER disclosed its third-quarter report for 2025, stating that the company's revenue for the first three quarters was 90.43 million yuan, a year-on-year decrease of 34.27%; the net profit attributable to the parent company was a loss of 29.38 million yuan; the net profit excluding non-recurring gains and losses was a loss of 37.25 million yuan; basic earnings per share were -0.16 yuan

    Zhitong·
    SH
    688317
    -4.46%
    Zhitong·
    SH
    688317
    -4.46%

    LIFERIVER: Plans to repurchase shares for 60 million to 120 million yuan

    LIFERIVER announced that the company plans to repurchase a portion of its issued ordinary shares through centralized bidding, with the repurchase amount not less than 60 million yuan and not exceeding 120 million yuan. The funding sources will be from its own funds and special loans for stock repurchase. The repurchase price will not exceed 37.99 yuan per share, and the repurchased shares are intended for the employee stock ownership plan or equity incentives

    Zhitong·
    SH
    688317
    -4.46%
    Zhitong·
    SH
    688317
    -4.46%

    LIFERIVER: Monkeypox virus nucleic acid testing kit (fluorescent PCR method) included in WHO emergency use list

    LIFERIVER announced that its monkeypox virus nucleic acid detection kit (fluorescent PCR method) has been included in the World Health Organization's Emergency Use Listing, effective September 17, 2025. This recognition will support the company's promotion and sales in overseas markets

    Zhitong·
    SH
    688317
    -4.46%
    Zhitong·
    SH
    688317
    -4.46%

    LIFERIVER: Has established a product line for the detection of mosquito-borne infectious diseases, including the Chikungunya virus

    LIFERIVER stated on the interactive platform that the company has established a product line for the detection of mosquito-borne infectious diseases, covering chikungunya virus, dengue virus, Zika virus, etc., compatible with fully automated molecular testing equipment, serving scenarios such as disease control centers, port quarantine, and third-party laboratories. For the chikungunya virus, the company has developed multiple testing kits that can be used for suspected case screening, close contact monitoring, and large-scale screening

    Zhitong·
    SH
    688317
    -4.46%
    Zhitong·
    SH
    688317
    -4.46%

    Monkeypox concept stocks surged, KHB hit the limit up

    The monkeypox concept has seen a surge, with KHB hitting the limit up, and DAJY, Yatai pharm, Lanwei Medical, WONDFO BIOTECH, Tellgen, and LIFERIVER also rising

    Zhitong·
    SZ
    002370
    -6.23%
    SZ
    002022
    -4.58%
    SZ
    300482
    -2.64%
    Zhitong·
    SZ
    002370
    -6.23%
    SZ
    002022
    -4.58%
    SZ
    300482
    -2.64%